(Hong Kong, 9 August 2021) – Hang Seng Indexes Company has licensed the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 Index to Tian Hong Asset Management Co., Ltd. (‘Tian Hong’) to serve as the underlying index for the creation of an exchange-traded fund (‘ETF’). The ETF was listed on the Shanghai Stock Exchange on 9 August 2021 with assets under management (‘AUM’) of RMB352 million as at 22 July 2021.
The Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 Index comprises the top 50 stocks in pharmaceutical and related industries that are listed in Shanghai, Shenzhen or Hong Kong and demonstrate relatively higher research & development investment and stronger momentum performance.
The new ETF will bring the number of exchange-traded products linked to indexes in the Hang Seng Family of Indexes to 105 – with listings on 15 different stock exchanges across the world. As of 30 July 2021, AUM in products passively tracking indexes in the Hang Seng Family of Indexes had reached a total of about USD39.9 billion.
For further details of the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 Index, please visit www.hsi.com.hk
– End –
About Hang Seng Indexes Company Limited
Hang Seng Indexes Company Limited (‘Hang Seng Indexes Company’) manages and compiles the Hang Seng Family of Indexes, which cover stocks listed in Hong Kong and Mainland China. Our index series includes the Hang Seng Index, the Hang Seng China Enterprises Index and the Hang Seng TECH Index, as well as Stock Connect, Greater Bay Area and sector-related indexes. As at the end of 2020, assets under management in products passively tracking indexes in the Hang Seng Family of Indexes had reached a total of about US$38 billion. Hang Seng Indexes Company is a wholly owned subsidiary of Hang Seng Bank. For further information on the Hang Seng Family of Indexes, please visit www.hsi.com.hk